Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
March 3, 2025 (Issue: 1723)
The FDA has approved suzetrigine (Journavx –
Vertex), a selective sodium channel blocker, for oral
treatment of moderate to severe acute pain in adults.
Suzetrigine is the first sodium channel blocker to be
approved in the US for this...more
- Nonopioid drugs for pain. Med Lett Drugs Ther 2022; 64:33.
- Opioids for pain. Med Lett Drugs Ther 2022; 64:193.
- JD Osteen et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther 2025 January 8 (epub). doi:10.1007/s40122-024-00697-0
- T Bertoch et al. Randomized, placebo-controlled, phase 3 trials of suzetrigine, a non-opioid, pain signal inhibitor for treatment of acute pain after abdominoplasty or bunionectomy. American Society of Anesthesiologists (ASA) Anesthesiology Annual Meeting 2024. Philadelphia, PA. October 18-22, 2024. Available at: https://bit.ly/3Cuq2YH. Accessed February 12, 2025.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_ PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. February 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.
- DM Rind et al. Suzetrigine for acute pain: effectiveness and value. Evidence report. Institute for Clinical and Economic Review, February 5, 2025. Available at: https://bit.ly/4aUbe2f. Accessed February 12, 2025.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain
Article code: 1723a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
